San Diego-based mostly Viking Therapeutics marked alone as a significant competitor during the weight loss drug market in February immediately after revealing promising facts from the mid-stage demo of experimental drug VK2735, which advised it rivaled—and outperformed—Novo and Lilly drugs when offered like a weekly injection and in March the c